PCSK9 Inhibitors: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Biochemistry & Molecular Biology
Contributor:
Mateusz Leśniewski

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel group of hypolipidemic drugs that are recommended particularly for high-risk hypercholesterolemia patients, including those with primary hypercholesterolemia (PH), where lifelong exposure to high low-density lipoprotein (LDL) cholesterol levels results in an elevated risk of atherosclerosis at an early age. The onset and progression of atherosclerosis is significantly influenced by activated platelets. Oxidized LDL influences platelet activation by interacting with their surface receptors and remodeling the composition of their cell membrane. This results in platelet aggregation, endothelial cell activation, promotion of inflammation and oxidative stress, and acceleration of lipid accumulation in atherosclerotic plaques. PCSK9 inhibitors reduce platelet activation by both significantly lowering LDL levels and reducing the LDL receptor-mediated activation of platelets by PCSK9. They also work synergistically with other hypolipidemic and antithrombotic drugs, including statins, ezetimibe, acetylsalicylic acid, clopidogrel, and ticagrelor, which enhances their antiplatelet and LDL-lowering effects. 

  • PCSK9 inhibitors
  • platelets

1. Primary Hypercholesterolemia

Primary hypercholesterolemia (PH) is a metabolic disorder characterized by elevated serum levels of low-density lipoprotein cholesterol (LDL-C). This lipid disorder is genetically heterogenous and involves both monogenic autosomal dominant familial hypercholesterolemia (FH), with a prevalence estimated at 1:250 [1], and the more frequent polygenic non-familial hypercholesterolemia [2]. Numerous epidemiological studies have proved a correlation between serum LDL-C levels and cardiovascular disease (CVD) [3][4][5][6][7]. Due to lifelong exposure to high cholesterol levels, individuals with PH have a greater risk of developing CVD, even at a relatively young age [8][9].

Three main genes have been identified as causative factors of FH in an autosomal dominant manner: the LDL receptor (LDLR), apolipoprotein B (ApoB), and the proprotein convertase subtilisin-kexin type 9 (PCSK9) [10]. There are also other rare forms of FH. These include mutations in the apolipoprotein E (ApoE) gene and LDL-C adaptor protein 1 (LDLRAP1) [11][12]. Polygenic non-familial hypercholesterolemia includes single nucleotide polymorphisms (SNPs) in several genes, involving common genes (LDLR, PCSK9) as well as less frequent genes, such as the ATP-binding cassette sub-family G member 8 gene (ABCG8) or cadherin EGF LAG seven-pass G-type receptor 2 gene (CELSR2) [13]. Both ABCG8 and CELSR2 encode proteins associated with transmembrane transport and receptor–ligand cellular interactions [14][15].

PH is associated with increased platelet reactivity. Activated platelets play a key role in atherosclerotic processes and the interaction between platelets and oxidized LDL (oxLDL) affects the formation of atherosclerotic plaques in several ways, which are discussed in detail later [16][17].

Until the early 2000s, long-term lipoprotein apheresis was the only treatment to improve outcomes in patients with severe FH [18]. In 2003, PCSK9 was discovered in some families, presenting with the clinical phenotype of FH yet without pathogenic DNA variants in either the LDLR or ApoB genes [19]. At that time, only these two genes were known to cause FH, and so a new responsible gene was suspected. Further genetic research identified a region on chromosome 1 that was linked to the presence of this phenotype [20][21]. Eventually, in 2003, scientists found that mutations in the PCSK9 gene were able to cause FH in those patients [22]. Since then, PCSK9 has become a baseline for several therapeutic agents, which significantly reduce the risk of cardiovascular events [23]. Recent findings show that PCSK9 inhibitors may lower LDL-C level, as well as decrease platelet activity [24]. Other pleiotropic effects of PCSK9 inhibitors, such as anti-atherosclerotic effects, stabilization of atherosclerotic plaques, antineoplastic effects, and the ability to influence the course of bacterial infections, have recently been comprehensively reviewed [25].

2. Pathophysiology

2.1. Development of Atherosclerotic Plaques

Atherosclerosis is a complex process consisting of several steps. First, LDL particles cross the arterial endothelium and accumulate in the intima or subendothelial layer [26]. This step is determined by the integrity of the endothelium. Regions with turbulent blood flow, such as arterial bifurcations, are more vulnerable to this process [27]. Numerous genetic factors, oxidative and mechanical stress, elevated serum homocysteine levels, and infections also contribute to this process [17]. Once in the intima, LDL is oxidized, triggering the expression of various adhesion and chemoattractant particles, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), platelet–endothelial cell adhesion molecule (PECAM-1), selectins, and integrins (CD11/CD18), driving the recruitment of macrophages to the site [28][29][30]. Within the arterial wall, macrophages begin to internalize ox-LDL via scavenger receptors, eventually transforming into foam cells [31]. This intensifies the ongoing inflammation [32], inducing the production and release of even more cytokines, which further promote the attraction of macrophages [33].

As the cycle repeats and additional lipids accumulate in the intima, a fibrous cap forms, composed mostly of a lipid-rich core and smooth muscle cell cap, which separates the atherosclerotic plaque from the blood flow [33]. The development of an atherosclerotic plaque is shown schematically in Figure 1.

Life 11 00466 g001 550

Figure 1. Scheme of atherosclerotic plaque development. IFN: interferon, IL: interleukin, LDL: low density lipoprotein, TNF-α: tumor necrosis factor α.

2.2. Mechanisms of Platelet Activation in Hypercholesterolemia

Platelet activation in hypercholesterolemic states occurs through several mechanisms, including: (i) scavenger receptor cluster of differentiation (CD)36, (ii) scavenger receptor lectin-like ox-LDL receptor-1 (LOX-1), and (iii) LDL-C triggered platelet membrane composition changes [34]. The mechanisms of platelet activation by LDL are shown in Figure 2.

Life 11 00466 g002 550

Figure 2. Mechanisms of platelet activation by LDL. ADP: adenosine diphosphate, CD: cluster of differentiation, LDL: low density lipoprotein, PCSK-9: proprotein convertase subtilisin-kexin type 9.

CD36 is a multi-functional class B scavenger receptor [35]. It is a transmembrane glycoprotein that is constitutively expressed in various cell types, including macrophages, platelets, and microvascular endothelial cells [35][36]. It is a ligand for a number of particles, such as thrombospondin-1, ox-LDL, fatty acids, microbial diacyloglycerides, and many others [35][37][38]. Previous studies have shown that the interaction of CD36 with ox-LDL triggers signaling pathways that activate platelets, inducing the expression of P-selectin and the activation of integrin αIIbβ3 (the receptor for fibrinogen), therefore facilitating the formation of platelet–leukocyte complexes via P-selectin and the cross-linking of adjacent platelets via fibrinogen [34][39]. The ox-LDL–CD36 interaction was shown to trigger platelet hyperreactivity via Src family kinases, Vav-guanine nucleotide exchange factors, cyclic guanosine monophosphate (cGMP), and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, producing reactive forms of oxygen and leading to a vicious circle of LDL oxidation and platelet activation [40][41]. The binding of ox-LDL to CD36 also induces the release of various chemokines, such as monocyte chemotactic protein-1 and the interleukin 1β precursor, leading to the progression of atherosclerosis [42][43]. CD36 activation is also an important factor contributing to ox-LDL platelet internalization and foam cell formation [34][43].

Another platelet receptor that is important in the development of atherosclerosis is LOX-1. It is a class E scavenger receptor involved in the regulation of ox-LDL uptake by endothelial cells and platelets [44][45]. Contrary to the native expression of CD36, LOX-1 expression is atheroma-related [34][46]. Binding between ox-LDL and LOX-1 leads to the activation of integrins αIIbβ3 and α2β1, which results in platelet shape change and aggregation, contributing to thrombus formation [44][45]. Ox-LDLs are also linked with high plasminogen activator inhibitor-1 levels and suppression of the fibrinolytic activity of endothelial cells [17].

Hypercholesterolemia can also contribute to platelet hyperreactivity via direct ox-LDL–platelet membrane interaction. As previous studies have shown, intrinsic platelet reactivity varies between individuals and increases with age [47]. LDL remodels the phospholipid composition of the platelet membrane by transferring phospholipids from lipoproteins, hence changing the structure of membrane phospholipids [48]. Therefore, high LDL-C levels activate platelets not only via intracellular signaling pathways, but also through direct lipid exchange [43].

2.3. Platelet Activation, Atherotogenesis, and Atherothrombosis

Platelet activation in hypercholesterolemia can promote thrombus formation on an injured artery, leading to arterial thrombosis [49], which is by far the most serious complication of atherosclerosis and can result in death from myocardial infarction or ischemic stroke [50]. However, even before thrombus formation, activated platelets can influence atherogenesis and atheroprogression, increasing the risk of future fatal thrombotic complications [51].

Ox-LDL-laden platelets not only induce endothelial inflammation, promoting vascular injury, but also inhibit the regeneration of the endothelium by reducing CD34+ progenitor cell differentiation into endothelial cells. Both of these processes promote atherogenesis initiation [52]. Platelets also influence atherosclerotic plaque development and destabilization by increasing lipid accumulation, monocyte migration, and foam cell formation (the key mediator of this process being the interaction between platelet P-selectin and P-selectin glycoprotein ligand-1 present on monocytes) [30]. Platelets also shape the immune response by releasing chemokines such as CXCL4, CCL5, and CXCL12 [53]. Moreover, ox-LDL-laden platelets can be phagocytosed by foam cells, directly increasing their lipid load [54].

Additionally, activated platelets can promote the activation of other platelets, increasing the atherogenic effect even more. Activated platelets can accelerate LDL-C oxidation through the generation of oxidative stress by platelet NADPH-oxidase 2, which further enhances platelet activation [55].

Platelet-Derived Extracellular Vesicles

Activated platelets release platelet-derived extracellular vesicles (PEVs) into the bloodstream, which can further increase platelet hyperreactivity [56][57]. EVs are membrane-enclosed mediators of cell–cell communication that are generated by various cells both in physiological and pathological states, and are heterogeneous both in terms of biogenesis and composition. PEVs constitute about 30% of all EVs detected in normal plasma [58].

PEVs may contain cyclooxygenase and thromboxane synthase, which can synthesize thromboxane, and thus promote platelet activation and aggregation. Moreover, PEVs can be used as substrates for the synthesis of arachidonic acid by phospholipase A2s, which in turn can be metabolized into thromboxane [59]. PEVs also contain various proteins characteristic of activated platelets and can therefore disseminate platelet activation [16]. It was shown that PEVs significantly increase fibrin deposition and platelet adhesion to the damaged vessel walls [60]. All these factors are responsible for the prothrombotic properties of PEVs.

PEVs can also promote inflammatory cytokine release and ox-LDL phagocytosis by macrophages, thereby accelerating foam cell formation and AS progression [61]. PEV interactions with the immune system and the resulting exacerbation of inflammation and oxidative stress can promote progression and destabilization of the atherosclerotic plaque and ox-LDL synthesis on various stages of atherosclerosis [16][62]. Additionally, PEVs may influence the adhesion of inflammatory cells and endothelial dysfunction, thus playing a part in the initial stages of atherosclerosis [16][63].

3. Markers of Platelet Activation in PH

Platelet activation can be detected through several markers, such as: (i) mean platelet volume, (ii) circulating PEV concentrations, (iii) platelet-derived inflammatory biomarkers, (iv) platelet-leukocyte aggregates, and (v) platelet-activating factor acetylhydrolase.

3.1. Mean Platelet Volume

One of the oldest, but still valuable, markers of platelet activation is mean platelet volume (MPV). Increased MPV is observed in various diseases and is associated with an increase in platelet activity and inflammation [64]. It has been shown that elevated MPV is associated with higher cardiovascular risk [62], however it should not be used as a standalone marker [64]. In PH, not only is MPV increased, but it is also independently associated with total cholesterol level [65].

3.2. Circulating PEV Levels

Liquid biopsy of circulating EVs may be a useful method for detecting atherosclerotic plaques and calcification in asymptomatic PH. In a study on eighty-two PH patients, the patients with atherosclerosis were characterized by higher levels of PEVs, regardless of lipid-lowering therapy. Combining PEV count with levels of other EVs resulted in 79.1% sensitivity and 45.8% specificity in detecting the presence of atherosclerotic plaques in PH patients [16]. Moreover, high levels of PEVs are present in young patients with high cardiovascular risk and are not completely normalized by lipid-lowering treatments [66]. Changes in the composition of EVs can also anticipate clinical events [67].

3.3. Platelet-Derived Inflammatory Biomarkers

Platelet factor 4 (PF4)/CXCL4, neutrophil activating peptide 2 (NAP2)/CXCL7, cluster of differentiation 40 ligand (CD40L), and regulated on activation normal T cell expressed and secreted (RANTES)/CCL5 were all found to be elevated in patients with FH, even in cases of intensive lipid-lowering treatment. This shows that despite platelet hyperactivation in FH being associated with elevated LDL-C levels, lowering blood LDL-C may not prevent all complications caused by platelet hyperreactivity [68].

3.4. Platelet–Leukocyte Aggregates

Platelets from PH patients express increased amounts of surface proteins such as P-selectin, resulting in a significantly higher tendency to create platelet–leukocyte aggregates. Not only is this a marker of the activation of platelets and leukocytes cells, but the presence of such aggregates also results in increased platelet and leukocyte adhesion to dysfunctional endothelium [69]. Platelet–leukocyte aggregate count is considered to be one of the most sensitive markers of platelet activation [70].

3.5. Platelet-Activating Factor Acetylhydrolase

Another platelet-associated marker that reflects the severity of hypercholesterolemia is platelet-activating factor acetylhydrolase (PAF-AH). It has been shown that the ratio of HDL-associated to LDL-associated PAF-AH decreases progressively from healthy to heterozygotic FH to homozygotic FH patients, and is proportional to the plasma LDL-C increase [71].

4. PCSK9 and PCSK9 Inhibitors

4.1. The Role of PCSK9

Expressed primarily in the liver, PCSK9 plays a key regulatory role in lipid metabolism [72][73]. As LDLR binds the LDL particle, the whole complex enters the endosomal pathway, eventually causing the degradation of LDL and releasing the LDLR back to the cell membrane [73]. PCSK9 binds to the LDLR on the cell surface, causing its internalization and lysosomal degradation [73]. This mechanism inhibits LDLR recycling, which normally allows one LDLR particle to process approximately 150 LDL particles [74][75].

Previous research reveals that PCSK9 overexpression is also regulated by non-genetic mechanisms [76]. Experimental data show that PCSK9 is induced by various inflammatory stimuli, such as lipopolysaccharides and zymosan, resulting in a significant increase in LDL-C levels [77]. Furthermore, ox-LDL also increases PCSK9 expression through the alteration of inflammatory cytokines such as interleukin (IL)-1α, IL-6, and tumor necrosis factor α (TNF-α) in macrophages [78]. This results in the progression of atherosclerosis, which involves platelets [17]. Interestingly, the siRNA-mediated knockdown of PCSK9 suppresses ox-LDL-induced proinflammatory chemokine synthesis [78].

4.2. PCKS9 and Platelets

There are many other receptors targeted by PCSK9 other than LDLR, such as CD36, low density lipoprotein receptor-related protein 1 (LRP-1), very low density lipoprotein receptor (VLDLR), and the apolipoprotein E receptor 2 (ApoER2) [79]. PCSK9 enhances platelet activation by binding to CD36, therefore contributing to atherosclerosis [79]. Besides lowering LDL-C level, PCSK9 inhibitor therapy showed a reduction in platelet reactivity and increased platelet sensitivity to the inhibitory effects of aspirin [24].

4.3. PCSK9 Inhibitors

Due to its function in lipid homeostasis, PCSK9 is a highly desirable target for therapeutic agents. Recently, a new class of drugs, PCSK9 inhibitors, has become available. The three members of this group available for patients in Europe are alirocumab, evolocumab and inclisiran.

Alirocumab and evolocumab are monoclonal antibodies (mAbs) that have been developed to bind PCSK9 and thus impair its function [80]. Clinical data show that the administration of PCSK9 mAbs is associated with an approximately 60% reduction in plasma LDL-C level in patients with both heterozygous FH and non-familial PH [81][82][83][84]. Anti-PCSK9 mAbs are injected subcutaneously. No major side effects have been described, yet there is the potential problem of autoantibodies [85]. Both alirocumab and evolocumab are fully human antibodies, and thus they are less likely to provoke such a reaction. However, few such incidents have been reported (without impairing the LDL-C lowering effect) [85].

Inclisiran is a relatively new drug that was authorized for use by the European Medicines Agency in December 2020. It is a silencing RNA (siRNA) particle targeting the hepatic production of PCSK9 [86]. Inclisiran selectively interferes with the expression of specific genes and catalytically silences the translation of the complementary target messenger RNA (mRNA), blocking the synthesis of PCSK9 [86]. Clinical trial data showed a 44% reduction in LDL-C level compared to placebo in heterozygous FH, and a 50% reduction in general hypercholesterolemic patients [87][88]. In contrary to mAbs, inclisiran needs to be administered twice a year, which is more convenient for patients than the twice-a-month injection of mAbs [86].

The indications for PCSK9-inhibitors include: (i) PH (heterozygous familial and non-familial) or mixed dyslipidaemia, (ii) homozygous FH, and (iii) established cardiovascular disease, in combination with diet and other lipid-lowering therapies [85]. Although PCSK9 inhibitors and inclisiran have great cholesterol-lowering potential in these patient populations, due to their novelty and high costs, they remain out of most patients’ reach [85].

5. Antiplatelet Effects of PCSK-9 Inhibitors

5.1. PCSK9 Inhibitors

The complex role of PCSK9 suggests that the impact of PCSK9 inhibition is not limited to the reduction of LDL-C, but that it also affects other aspects of PCSK9 activity, such as lipid metabolism and platelet function [89][90]. Moreover, as ox-LDL is a crucial factor for increasing platelet hyperreactivity, LDL-lowering treatment also affects platelets [91]. Until now, it has not been established whether PCSK9 inhibitors exert a direct inhibitory effect on platelet function, or whether this effect is secondary to the strong lipid-lowering potential of PCSK9 inhibitors [80][81][92].

In animal models, administration of the PCSK9-surpressing agent 10-dehydrogingerdione decreased both PSCK9 level and the concentration of platelet activation markers, such as soluble CD40 ligand and soluble P-selectin [93]. Concurrently, PCSK9 deficiency has been reported to attenuate thrombosis in mice [94]. Two studies conducted on small groups of patients receiving PCSK9 inhibitors in monotheraphy showed reduced platelet reactivity [24][95], further supporting the antiplatelet effects of PCSK9 inhibitors. No adverse effects on platelet counts were reported in patients receiving inclisiran [96]. Although the preliminary results are promising, there is still a lack of evidence-based data to draw firm conclusions regarding the mechanisms and magnitude of action of PCSK9 inhibitors, especially in monotherapy. For example, the effect of PCSK9 inhibitors on the concentrations of prostacyclin or thromboxane A2 and on platelet lifespan is still unknown, indicating that further research is needed to shed more light on this topic.

Besides the antiplatelet effects, higher PCSK9 levels were shown to accelerate the development of atherosclerotic plaques and increase the size of plaque necrotic cores, independent of lipid changes [97][98]. PCSK9 not only promotes ox-LDL internalization, both through interaction with LOX-1 and the increase in LDL level, but it also sensitizes cells to ox-LDL, which aggravates ongoing inflammatory processes. PCSK9 also stimulates dendritic cell maturation, which can in turn induce PCSK9, and T-cell proliferation [98]. Treatment with PCSK9 inhibitors was shown to: (i) decrease the formation of foam cells; (ii) inhibit the production of pro-inflammatory cytokines, including IL-1α, IL-6, and TNF-α, and the activation of proinflammatory pathways, such as the TLR4/NF-κB/COX-2 pathway; and (iii) suppress the migration and proliferation of smooth muscle cells [98][99][100]. PCSK9 inhibitors also decrease serum levels of cytokines associated with endothelial activation and monocyte/macrophage migration [99]. A human study showed that even a short-term therapy with PCSK9 inhibitors improves endothelial function, which is proportional to LDL reduction [101].

5.2. Statins and PCSK9 Inhibitors

Statin therapy is the first line of treatment for PH [85]. However, despite the high effectiveness of statins, there is considerable variability in the individual treatment response [102]. Even maximum doses may not achieve blood LDL-C targets, especially in patients with particularly high pre-treatment LDL-C levels. If the treatment goal is not achieved through therapy with statins and ezetimibe, treatment with a PCSK9 inhibitor is recommended [85].

It was found that PCSK9 polymorphisms can influence the therapeutic effect of statins [103]. It has also been suggested that slightly higher pre-treatment serum levels of PCSK9 may distinguish patients who do not respond to stain treatment [104]. Furthermore, it was found that statin therapy causes a significant increase in plasma PCSK9 concentration [105]. It has been suggested that this might be the reason for the nonlinear relationship between statin dose and LDL-C reduction, where at some point, increasing the statin dose does not exert additional effects on LDL-C levels [106].

Monotherapy with statins reduces platelet activation and inflammation [107]; however, this effect is significantly correlated with LDL-C reduction [91]. In contrast, PCSK9 inhibitors were found to reduce platelet reactivity, both directly and through their LDL-lowering effect [24]. They also promote atherosclerotic plaque stabilization [108]. As a result, adding PCSK9 inhibitors to statin therapy significantly improves cardiovascular outcomes, both due to the lipid-lowering and antiplatelet effects [109][110][111].

5.3. Ezetimibe and PCSK9 Inhibitors

Adding ezetimibe to statin therapy can further reduce LDL-C levels and improve endothelial function [112], but the LDL-lowering effect of ezetimibe is lower than that of PCSK9 inhibitors [113]. Ezetimibe also significantly reduces the expression of P-selectin and CD40L on the surface of free platelets; however, this effect was not observed in platelets in direct contact with endothelial cells [114].

Ezetimibe targets microsomal triglyceride transfer protein (MTP) and NPC1L1, which are upregulated as a result of PCSK9 increase [115], which occurs during both ezetimibe and statin therapy, and this effect is increased even more when both drugs are used simultaneously [116]. Therefore, ezetimibe and PCSK9 inhibitors work synergistically and both can be seen as a complement of statin therapy [85][115].

5.4. Antithrombotic Therapy and PCSK9 Inhibitors

Antithrombotic therapy is a crucial part of atherosclerosis treatment [117], and pre-clinical trials show that it is also useful before the late stage of hypercholesterolemia, as a method of inhibiting the hypercholesterolemia–inflammation loop to stop the initiation and progression of atherosclerosis [118]. This effect is better documented in the case of P2Y12 inhibitors, clopidogrel and ticagrelor, than acetylsalicylic acid (ASA) [117]. A study on ticagrelor showed that its atherosclerosis-alleviating effect may be linked to PSCK9 downregulation [119].

However, in up to 30% of patients, platelets show decreased sensitivity to antithrombotic therapy. It has been shown that the suboptimal response to ASA can be linked to hypercholesterolemic states, and that lipid lowering therapy may improve the response [120]. A similar correlation has been found between clopidogrel responsiveness and LDL-C level [121]. In the case of prasugrel and ticagrelor, PCSK9 levels have been shown to correlate with platelet activity during treatment [122]. Therefore, combining antithrombotic therapy with PCSK9 inhibitors can have beneficial effects both on platelet activity and atherosclerosis progression.

A summary of the studies investigating the effects of PCSK9 inhibitors or PCSK9 levels on platelet function parameters is shown in Table 1.

Table 1. Summary of studies investigating the effects of PCSK9 inhibitors or PCSK9 levels on platelet function parameters. PH: primary hypercholesterolemia, FH: familial hypercholesterolemia, LDL-C: low-density lipoprotein cholesterol, sP-selectin: soluble P-selectin, sCD40L: soluble CD40 ligand.

PCSK-9 Inhibitor Population Effect Ref.
Monotherapy
Alirocumab/evolocumab Patients with PH (n = 7) Decrease in P-selectin exposure, with and without agonists [24]
Alirocumab/evolocumab Patients with hypercholesterolemia (n = 21) Reduced platelet reactivity to agonists [95]
Alirocumab Patients with FH (n = 736) LDL-C lowering [81]
Evolocumab Patients with FH (n = 331) LDL-C lowering [92]
10-Dehydrogingerdione Rabbits (n = 30) Decrease in sP-selectin and sCD40L [93]
PCSK9 deficiency Mice (n = 20) Lowered risk of venous thrombosis [94]
Polytherapy
Alirocumab + statin (unspecified) Patients with hypercholesterolemia (n = 18,924) Decreased risk of thrombotic events [110]
Evolocumab + statin (unspecified) Patients after acute coronary syndrome (n = 18,924) Decreased risk of venous thromboembolism [111]
Evolocumab + rosuvastatin Patients with de novo acute coronary artery disease (n = 64) Stabilization of atherosclerotic plaque [108]
Loss-of-funcion mutation in PCSK9 gene + statin (unspecified) Patients with hypercholesterolemia (n = 2388) Improved response to statin therapy [103]
Alirocumab/evolocumab + aspirin Patients with PH (n = 14) Decrease in P-selectin exposure, with and without stimuli [24]
Alirocumab + aspirin In vitro study (n = 10) Decrease in platelet aggregation [79]
Lower levels of PCSK9 + ticagrelor Patients with acute coronary syndrome (n = 333) Decrease in platelet aggregation [122]

This entry is adapted from the peer-reviewed paper 10.3390/life11060466

References

  1. Akioyamen, L.E.; Genest, J.; Shan, S.D.; Reel, R.L.; Albaum, J.M.; Chu, A.; Tu, J.V. Estimating the prevalence of heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis. BMJ Open 2017, 7, e016461.
  2. Langslet, G.; Emery, M.; Wasserman, S.M. Evolocumab (AMG 145) for primary hypercholesterolemia. Expert Rev. Cardiovasc. Ther. 2015, 13, 477–488.
  3. Yusuf, S.; Hawken, S.; Ôunpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J.; et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004, 364, 937–952.
  4. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L.E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E.H.; Keech, A.; et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376, 1670–1681.
  5. Emerging Risk Factors Collaboration; Di Angelantonio, E.; Gao, P.; Pennells, L.; Kaptoge, S.; Caslake, M.; Thompson, A.; Butterworth, A.S.; Sarwar, N.; Wormser, D.; et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012, 307, 2499–2506.
  6. Jeong, S.; Choi, S.; Kim, K.; Kim, S.M.; Lee, G.; Park, S.Y.; Kim, Y.; Son, J.S.; Yun, J.; Park, S.M. Effect of Change in Total Cholesterol Levels on Cardiovascular Disease Among Young Adults. J. Am. Hear. Assoc. 2018, 7.
  7. Park, J.S.; Cha, K.S.; Lee, H.W.; Oh, J.-H.; Choi, J.H.; Lee, H.C.; Hong, T.J.; Jeong, M.H.; Chae, S.C.; Kim, Y.J. Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction. Cardiol. J. 2013, 26, 176–185.
  8. Van der Graaf, A.; Hutten, B.A.; Kastelein, J.J.; Vissers, M.N. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia. Expert. Rev. Cardiovasc. Ther. 2006, 4, 345–351.
  9. Navar-Boggan, A.M.; Peterson, E.D.; D’Agostino, S.R.B.; Neely, B.; Sniderman, A.D.; Pencina, M.J. Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. Circulation 2015, 131, 451–458.
  10. Vuorio, A.; Watts, G.F.; Schneider, W.J.; Tsimikas, S.; Kovanen, P.T. Familial hypercholesterolemia and elevated lipoprotein(a): Double heritable risk and new therapeutic opportunities. J. Intern. Med. 2019, 287, 2–18.
  11. Benito-Vicente, A.; Uribe, K.B.; Jebari, S.; Galicia-Garcia, U.; Ostolaza, H.; Martin, C. Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. Int. J. Mol. Sci. 2018, 19, 3426.
  12. Rios, J.; Stein, E.; Shendure, J.; Hobbs, H.H.; Cohen, J.C. Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum. Mol. Genet. 2010, 19, 4313–4318.
  13. Talmud, P.J.; Shah, S.; Whittall, R.; Futema, M.; Howard, P.; A Cooper, J.; Harrison, S.C.; Li, K.; Drenos, F.; Karpe, F.; et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. Lancet 2013, 381, 1293–1301.
  14. Yu, L.; Gupta, S.; Xu, F.; Liverman, A.D.B.; Moschetta, A.; Mangelsdorf, D.J.; Repa, J.J.; Hobbs, H.H.; Cohen, J.C. Expression of ABCG5 and ABCG8 Is Required for Regulation of Biliary Cholesterol Secretion. J. Biol. Chem. 2005, 280, 8742–8747.
  15. Al-Eitan, L.N.; Elsaqa, B.Z.; Almasri, A.Y.; A Aman, H.; Khasawneh, R.H.; A Alghamdi, M. Influence of PSRC1, CELSR2, and SORT1 Gene Polymorphisms on the Variability of Warfarin Dosage and Susceptibility to Cardiovascular Disease. Pharm. Pers. Med. 2020, 13, 619–632.
  16. Chiva-Blanch, G.; Badimon, L. Cross-Talk between Lipoproteins and Inflammation: The Role of Microvesicles. J. Clin. Med. 2019, 8, 2059.
  17. Mollazadeh, H.; Carbone, F.; Montecucco, F.; Pirro, M.; Sahebkar, A. Oxidative burden in familial hypercholesterolemia. J. Cell. Physiol. 2018, 233, 5716–5725.
  18. Mickiewicz, A.; Borowiec-Wolna, J.; Bachorski, W.; Gilis-Malinowska, N.; Gałąska, R.; Raczak, G.; Chmara, M.; Wasąg, B.; Jaguszewski, M.J.; Fijałkowski, M.; et al. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre. Cardiol. J. 2020, 26, 669–679.
  19. Rosenson, R.S.; Hegele, R.A.; Fazio, S.; Cannon, C.P. The Evolving Future of PCSK9 Inhibitors. J. Am. Coll. Cardiol. 2018, 72, 314–329.
  20. Haddad, L.; Day, I.N.; Hunt, S.; Williams, R.R.; E Humphries, S.; Hopkins, P.N. Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred. J. Lipid Res. 1999, 40, 1113–1122.
  21. Varret, M.; Rabès, J.-P.; Saint-Jore, B.; Cenarro, A.; Marinoni, J.-C.; Civeira, F.; Devillers, M.; Krempf, M.; Coulon, M.; Thiart, R.; et al. A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p. Am. J. Hum. Genet. 1999, 64, 1378–1387.
  22. Abifadel, M.; Varret, M.; Rabès, J.-P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34, 154–156.
  23. Guedeney, P.; Giustino, G.; Sorrentino, S.; E Claessen, B.; Camaj, A.; Kalkman, D.N.; Vogel, B.; Sartori, S.; De Rosa, S.; Baber, U.; et al. Efficacy and safety of alirocumab and evolocumab: A systematic review and meta-analysis of randomized controlled trials. Eur. Heart J. 2019.
  24. Barale, C.; Bonomo, K.; Frascaroli, C.; Morotti, A.; Guerrasio, A.; Cavalot, F.; Russo, I. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutr. Metab. Cardiovasc. Dis. 2020, 30, 282–291.
  25. Basiak, M.; Kosowski, M.; Cyrnek, M.; Bułdak, Ł.; Maligłówka, M.; Machnik, G.; Okopień, B. Pleiotropic Effects of PCSK-9 Inhibitors. Int. J. Mol. Sci. 2021, 22, 3144.
  26. Schwenke, D.C.; E Carew, T. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arter. Off. J. Am. Hear. Assoc. Inc. 1989, 9, 908–918.
  27. Heo, K.-S.; Fujiwara, K.; Abe, J.-I. Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction. Circ. J. 2011, 75, 2722–2730.
  28. Van Haelst, P.L.; van Doormaal, J.J.; Asselbergs, F.W.; van Roon, A.M.; Veeger, N.J.; Henneman, M.M.; Smit, A.J.; Tervaert, J.W.; May, J.F.; Gans, R.O. Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia. Clin. Sci. 2003, 104, 627–632.
  29. Rahman, T.; Hamzan, N.S.; Mokhsin, A.; Rahmat, R.; Ibrahim, Z.O.; Razali, R.; Thevarajah, M.; Nawawi, H. Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members: A case control study. Lipids Heal. Dis. 2017, 16, 1–12.
  30. Badrnya, S.; Schrottmaier, W.; Kral, J.B.; Yaiw, K.-C.; Volf, I.; Schabbauer, G.; Söderberg-Nauclér, C.; Assinger, A. Platelets Mediate Oxidized Low-Density Lipoprotein–Induced Monocyte Extravasation and Foam Cell Formation. Arter. Thromb. Vasc. Biol. 2014, 34, 571–580.
  31. Moore, K.J.; Freeman, M.W. Scavenger receptors in atherosclerosis: Beyond lipid uptake. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1702–1711.
  32. Jukema, R.A.; Ahmed, T.A.N.; Tardif, J.-C. Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies. BMC Med. 2019, 17, 1–9.
  33. Marchio, P.; Guerra-Ojeda, S.; Vila, J.M.; Aldasoro, M.; Victor, V.M.; Mauricio, M.D. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxid. Med. Cell. Longev. 2019, 2019, 1–32.
  34. Gąsecka, A.; Rogula, S.; Szarpak, Ł.; Filipiak, K.J. LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis. Life 2021, 11, 39.
  35. Febbraio, M.; Hajjar, D.P.; Silverstein, R.L. CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Investig. 2001, 108, 785–791.
  36. Valiyaveettil, M.; Podrez, E.A. Platelet hyperreactivity, scavenger receptors and atherothrombosis. J. Thromb. Haemost. 2009, 7, 218–221.
  37. Hoebe, K.; Georgel, P.; Rutschmann, S.; Du, X.; Mudd, S.; Crozat, K.; Sovath, S.; Shamel, L.; Hartung, T.; Zähringer, U.; et al. CD36 is a sensor of diacylglycerides. Nat. Cell Biol. 2005, 433, 523–527.
  38. Bodart, V.; Febbraio, M.; Demers, A.; McNicoll, N.; Pohankova, P.; Perreault, A.; Sejlitz, T.; Escher, E.; Silverstein, R.; Lamontagne, D.; et al. CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart. Circ. Res. 2002, 90, 844–849.
  39. A Podrez, E.; Byzova, T.V.; Febbraio, M.; Salomon, R.G.; Ma, Y.; Valiyaveettil, M.; Poliakov, E.; Sun, M.; Finton, P.J.; Curtis, B.R.; et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 2007, 13, 1086–1095.
  40. Yang, M.; Silverstein, R.L. CD36 and ERK5 link dyslipidemia to apoptotic-like platelet procoagulant function. Curr. Opin. Hematol. 2019, 26, 357–365.
  41. Marcus, A.J.; Silk, S.T.; Safier, L.B.; Ullman, H.L. Superoxide production and reducing activity in human platelets. J. Clin. Investig. 1977, 59, 149–158.
  42. Cha, J.K.; Jeong, M.H.; Bae, H.R.; Han, J.Y.; Jeong, S.J.; Jin, H.J.; Lim, Y.J.; Kim, S.H.; Kim, J.W. Activated platelets induce secretion of interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-1alpha and surface expression of intercellular adhesion molecule-1 on cultured endothelial cells. J. Korean Med. Sci. 2000, 15, 273–278.
  43. Siegel-Axel, D.; Daub, K.; Seizer, P.; Lindemann, S.; Gawaz, M. Platelet lipoprotein interplay: Trigger of foam cell formation and driver of atherosclerosis. Cardiovasc. Res. 2008, 78, 8–17.
  44. Xu, S.; Ogura, S.; Chen, J.; Little, P.J.; Moss, J.; Liu, P. LOX-1 in atherosclerosis: Biological functions and pharmacological modifiers. Cell. Mol. Life Sci. 2013, 70, 2859–2872.
  45. Sawamura, T.; Kakino, A.; Fujita, Y. LOX-1: A multiligand receptor at the crossroads of response to danger signals. Curr. Opin. Lipidol. 2012, 23, 439–445.
  46. Kataoka, H.; Kume, N.; Miyamoto, S.; Minami, M.; Moriwaki, H.; Murase, T.; Sawamura, T.; Masaki, T.; Hashimoto, N.; Kita, T. Expression of Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 in Human Atherosclerotic Lesions. Circulation 1999, 99, 3110–3117.
  47. Price, J.; Lord, J.M.; Harrison, P. Inflammaging and platelet hyperreactivity: A new therapeutic target? J. Thromb. Haemost. 2020, 18, 3–5.
  48. Engelmann, B.; Kögl, C.; Kulschar, R.; Schaipp, B. Transfer of phosphatidylcholine, phosphatidylethanolamine and sphingomyelin from low- and high-density lipoprotein to human platelets. Biochem. J. 1996, 315, 781–789.
  49. Lacoste, L.; Lam, J.Y.; Hung, J.; Letchacovski, G.; Solymoss, C.B.; Waters, D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995, 92, 3172–3177.
  50. Herrington, W.; Lacey, B.; Sherliker, P.; Armitage, J.; Lewington, S. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ. Res. 2016, 118, 535–546.
  51. Lievens, D.; von Hundelshausen, P. Platelets in atherosclerosis. Thromb. Haemost 2011, 106, 827–838.
  52. Daub, K.; Seizer, P.; Stellos, K.; Krämer, B.F.; Bigalke, B.; Schaller, M.; Fateh-Moghadam, S.; Gawaz, M.; Lindemann, S. Oxidized LDL-Activated Platelets Induce Vascular Inflammation. Semin. Thromb. Hemost. 2010, 36, 146–156.
  53. Von Hundelshausen, P.; Schmitt, M.M. Platelets and their chemokines in atherosclerosis-clinical applications. Front. Physiol. 2014, 5, 294.
  54. Daub, K.; Langer, H.; Seizer, P.; Stellos, K.; May, A.E.; Goyal, P.; Bigalke, B.; Schönberger, T.; Geisler, T.; Siegel-Axel, D.; et al. Platelets induce differentiation of human CD34 + progenitor cells into foam cells and endothelial cells. FASEB J. 2006, 20, 2559–2561.
  55. Carnevale, R.; Bartimoccia, S.; Nocella, C.; Di Santo, S.; Loffredo, L.; Illuminati, G.; Lombardi, E.; Boz, V.; Del Ben, M.; De Marco, L.; et al. LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism. Atherosclerosis 2014, 237, 108–116.
  56. Gasecka, A.; Nieuwland, R.; Budnik, M.; Dignat-George, F.; Eyileten, C.; Harrison, P.; Huczek, Z.; Kapłon-Cieślicka, A.; Lacroix, R.; Opolski, G.; et al. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction. Platelets 2018, 31, 26–32.
  57. Gasecka, A.; Böing, A.N.; Filipiak, K.J.; Nieuwland, R. Platelet extracellular vesicles as biomarkers for arterial thrombosis. Platelets 2016, 28, 228–234.
  58. Gasecka, A.; Nieuwland, R.; Siljander, P.R.-M. Platelet-Derived Extracellular Vesicles. In Platelets; Elsevier: Amsterdam, The Netherlands, 2019; pp. 401–416.
  59. Boilard, E. Thematic Review Series: Exosomes and Microvesicles: Lipids as Key Components of their Biogenesis and Functions Extracellular vesicles and their content in bioactive lipid mediators: More than a sack of microRNA. J. Lipid Res. 2018, 59, 2037–2046.
  60. Suades, R.; Padró, T.; Vilahur, G.; Badimon, L. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb. Haemost. 2012, 108, 1208–1219.
  61. Feng, C.; Chen, Q.; Fan, M.; Guo, J.; Liu, Y.; Ji, T.; Zhu, J.; Zhao, X. Platelet-derived microparticles promote phagocytosis of oxidized low-density lipoprotein by macrophages, potentially enhancing foam cell formation. Ann. Transl. Med. 2019, 7, 477.
  62. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study. Lancet 2012, 380, 2095–2128.
  63. Lovren, F.; Verma, S. Evolving Role of Microparticles in the Pathophysiology of Endothelial Dysfunction. Clin. Chem. 2013, 59, 1166–1174.
  64. Korniluk, A.; Koper-Lenkiewicz, O.M.; Kamińska, J.; Kemona, H.; Dymicka-Piekarska, V. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediat. Inflamm. 2019, 2019, 1–14.
  65. Icli, A.; Aksoy, F.; Nar, G.; Kaymaz, H.; Alpay, M.F.; Nar, R.; Guclu, A.; Arslan, A.; Dogan, A. Increased Mean Platelet Volume in Familial Hypercholesterolemia. Angiol. 2015, 67, 146–150.
  66. Suades, R.; Padró, T.; Alonso, R.; Mata, P.; Badimon, L. High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis. Thromb. Haemost. 2015, 114, 1310–1321.
  67. Escate, R.; Padró, T.; Suades, R.; Camino, S.; Muñiz, O.; Diaz-Diaz, J.L.; Sionis, A.; Mata, P.; Badimon, L. High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients. Cardiovasc. Res. 2021, 117, 109–122.
  68. Hovland, A.; Narverud, I.; Øyri, L.K.L.; Bogsrud, M.P.; Aagnes, I.; Ueland, T.; Mulder, M.; Leijten, F.; Langslet, G.; Wium, C.; et al. Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers. J. Clin. Lipidol. 2021, 15, 134–141.
  69. Collado, A.; Marques, P.; Domingo, E.; Perello, E.; González-Navarro, H.; Martinez-Hervás, S.; Real, J.T.; Piqueras, L.; Ascaso, J.F.; Sanz, M.-J. Novel Immune Features of the Systemic Inflammation Associated with Primary Hypercholesterolemia: Changes in Cytokine/Chemokine Profile, Increased Platelet and Leukocyte Activation. J. Clin. Med. 2018, 8, 18.
  70. Khera, A.V.; Won, H.H.; Peloso, G.M.; Lawson, K.S.; Bartz, T.M.; Deng, X.; van Leeuwen, E.M.; Natarajan, P.; Emdin, C.A.; Bick, A.G.; et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J. Am. Coll. Cardiol. 2016, 67, 2578–2589.
  71. Tsimihodimos, V.; Karabina, S.-A.P.; Tambaki, A.P.; Bairaktari, E.; Miltiadous, G.; Goudevenos, J.A.; Cariolou, M.A.; Chapman, M.J.; Tselepis, A.D.; Elisaf, M. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res. 2002, 43, 256–263.
  72. Melendez, Q.M.; Krishnaji, S.T.; Wooten, C.J.; Lopez, D. Hypercholesterolemia: The role of PCSK. Arch. Biochem. Biophys. 2017, 625-626, 39–53.
  73. Li, S.; Li, J.-J. PCSK9: A key factor modulating atherosclerosis. J. Atheroscler. Thromb. 2015, 22, 221–230.
  74. Goldstein, J.L.; Brown, M.S.; Anderson, R.G.W.; Russell, D.; Schneider, W.J. Receptor-Mediated Endocytosis: Concepts Emerging from the LDL Receptor System. Annu. Rev. Cell Biol. 1985, 1, 1–39.
  75. Dietschy, J.M.; Turley, S.D.; Spady, D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 1993, 34, 1637–1659.
  76. Lakoski, S.G.; Lagace, T.A.; Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Genetic and Metabolic Determinants of Plasma PCSK9 Levels. J. Clin. Endocrinol. Metab. 2009, 94, 2537–2543.
  77. Feingold, K.R.; Moser, A.H.; Shigenaga, J.K.; Patzek, S.M.; Grunfeld, C. Inflammation stimulates the expression of PCSK. Biochem. Biophys. Res. Commun. 2008, 374, 341–344.
  78. Tang, Z.; Jiang, L.; Peng, J.; Ren, Z.; Wei, D.; Wu, C.; Pan, L.; Jiang, Z.; Liu, L. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int. J. Mol. Med. 2012, 30, 931–938.
  79. Qi, Z.; Hu, L.; Zhang, J.; Yang, W.; Liu, X.; Jia, D.; Yao, Z.; Chang, L.; Pan, G.; Zhong, H.; et al. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD. Circulation 2021, 143, 45–61.
  80. McDonagh, M.; Peterson, K.; Holzhammer, B.; Fazio, S. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. J. Manag. Care Spéc. Pharm. 2016, 22, 641–653.
  81. Kastelein, J.J.; Ginsberg, H.N.; Langslet, G.; Hovingh, G.K.; Ceska, R.; Dufour, R.; Blom, D.; Civeira, F.; Krempf, M.; Lorenzato, C.; et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 2015, 36, 2996–3003.
  82. Ogura, M. PCSK9 inhibition in the management of familial hypercholesterolemia. J. Cardiol. 2018, 71, 1–7.
  83. Tomlinson, B.; Hu, M.; Zhang, Y.; Chan, P.; Liu, Z.M. Alirocumab for the treatment of hypercholesterolemia. Expert Opin. Biol. Ther. 2017, 17, 633–643.
  84. Robinson, J.G.; Nedergaard, B.S.; Rogers, W.J.; Fialkow, J.; Neutel, J.M.; Ramstad, D.; Somaratne, R.; Legg, J.C.; Nelson, P.; Scott, R.; et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial. JAMA 2014, 311, 1870–1882.
  85. Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 2020, 41, 111–188.
  86. E Kosmas, C.; Estrella, A.M.; Skavdis, A.; Genao, E.P.; Martinez, I.; Guzman, E. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Ther. Clin. Risk Manag. 2020, 16, 1031–1037.
  87. Raal, F.J.; Kallend, D.; Ray, K.K.; Turner, T.; Koenig, W.; Wright, R.S.; Wijngaard, P.L.; Curcio, D.; Jaros, M.J.; Leiter, L.A.; et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N. Engl. J. Med. 2020, 382, 1520–1530.
  88. Ray, K.K.; Wright, R.S.; Kallend, D.; Koenig, W.; Leiter, L.A.; Raal, F.J.; Bisch, J.A.; Richardson, T.; Jaros, M.; Wijngaard, P.L.; et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N. Engl. J. Med. 2020, 382, 1507–1519.
  89. Bittner, V. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors? Circulation 2016, 134, 1695–1696.
  90. Paciullo, F.; Momi, S.; Gresele, P. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention. Thromb. Haemost. 2019, 119, 359–367.
  91. Barale, C.; Frascaroli, C.; Senkeev, R.; Cavalot, F.; Russo, I. Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. BioMed Res. Int. 2018, 2018, 1–11.
  92. Raal, F.J.; A Stein, E.; Dufour, R.; Turner, T.; Civeira, F.; Burgess, L.; Langslet, G.; Scott, R.; Olsson, A.G.; Sullivan, D.; et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet 2015, 385, 331–340.
  93. El-Seweidy, M.M.; Amin, R.S.; Atteia, H.H.; El-Zeiky, R.R.; Al-Gabri, N.A. Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione. Biomed. Pharmacother. 2019, 110, 456–464.
  94. Wang, H.; Wang, Q.; Wang, J.; Guo, C.; Kleiman, K.; Meng, H.; Knight, J.S.; Eitzman, D.T. Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice. Sci. Rep. 2017, 7, 1–8.
  95. Barale, C.; Bonomo, K.; Noto, F.; Traversa, M.; Cavalot, F.; Iozzia, M.; Frascaroli, C.; Guerrasio, A.; Russo, I. Effects of PCSK9 inhibitors on platelet function in adults with hypercholesterolemia. Atherosclerosis 2017, 263, e30–e31.
  96. Landmesser, U.; Haghikia, A.; A Leiter, L.; Wright, R.S.; Kallend, D.; Wijngaard, P.; Stoekenbroek, R.; Kastelein, J.J.P.; Ray, K.K. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: A pre-specified analysis from ORION. Cardiovasc. Res. 2021, 117, 284–291.
  97. Cheng, J.M.; Oemrawsingh, R.M.; Garcia-Garcia, H.M.; Boersma, E.; van Geuns, R.-J.; Serruys, P.W.; Kardys, I.; Akkerhuis, K.M. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis 2016, 248, 117–122.
  98. Ruscica, M.; Tokgözoğlu, L.; Corsini, A.; Sirtori, C.R. PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis 2019, 288, 146–155.
  99. Momtazi-Borojeni, A.A.; Sabouri-Rad, S.; Gotto, A.M.; Pirro, M.; Banach, M.; Awan, Z.; Barreto, G.E.; Sahebkar, A. PCSK9 and inflammation: A review of experimental and clinical evidence. Eur. Heart J. Cardiovasc. Pharmacother. 2019, 5, 237–245.
  100. Bao, H.L.; Liao, F.J.; Fang, L.; Zhong, F.; Liu, W.; Li, J.Q. Effect and mechanism of PCSK9 on lectin-like oxidized low-density lipoprotein receptor-1 mediated oxidized low-density lipoprotein uptake by THP-1 derived macrophages. Zhonghua Xin Xue Guan Bing Za Zhi 2019, 47, 367–373.
  101. Maulucci, G.; Cipriani, F.; Russo, D.; Casavecchia, G.; Di Staso, C.; Di Martino, L.; Ruggiero, A.; Di Biase, M.; Brunetti, N.D. Improved endothelial function after short-term therapy with evolocumab. J. Clin. Lipidol. 2018, 12, 669–673.
  102. Ridker, P.M.; Mora, S.; Rose, L. Percent reduction in LDL cholesterol following high-intensity statin therapy: Potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur. Heart J. 2016, 37, 1373–1379.
  103. Feng, Q.; Wei, W.-Q.; Chung, C.P.; Levinson, R.T.; Bastarache, L.; Denny, J.C.; Stein, C.M. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharm. J. 2017, 17, 204–208.
  104. Taylor, B.A.; Panza, G.; Pescatello, L.S.; Chipkin, S.; Gipe, D.; Shao, W.; White, C.M.; Thompson, P.D. Serum PCSK9 Levels Distinguish Individuals Who Do Not Respond to High-Dose Statin Therapy with the Expected Reduction in LDL-C. J. Lipids 2014, 2014, 1–3.
  105. Sahebkar, A.; Simental-Mendía, L.E.; Guerrero-Romero, F.; Golledge, J.; Watts, G.F. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials. Diabetes Obes. Metab. 2015, 17, 1042–1055.
  106. Taylor, B.A.; Thompson, P.D. Statins and Their Effect on PCSK9—Impact and Clinical Relevance. Curr. Atheroscler. Rep. 2016, 18, 1–6.
  107. Kim, C.J.; Han, E.J.; Chu, E.-H.; Hwang, B.-H.; Kim, J.-J.; Seung, K.-B.; Kim, S.H.; O, J.H.; Chang, K. Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery. Cardiol. J. 2020, 27, 762–771.
  108. Yano, H.; Horinaka, S.; Ishimitsu, T. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J. Cardiol. 2020, 75, 289–295.
  109. Steffens, D.; Bramlage, P.; Scheeff, C.; Kasner, M.; Hassanein, A.; Friebel, J.; Rauch-Kröhnert, U. PCSK9 inhibitors and cardiovascular outcomes. Expert Opin. Biol. Ther. 2019, 20, 35–47.
  110. Schwartz, G.G.; Steg, P.G.; Szarek, M.; Bittner, V.A.; Diaz, R.; Goodman, S.G.; Kim, Y.U.; Jukema, J.W.; Pordy, R.; Roe, M.T.; et al. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 2020, 141, 1608–1617.
  111. Marston, N.A.; Gurmu, Y.; Melloni, G.E.; Bonaca, M.; Gencer, B.; Sever, P.S.; Pedersen, T.R.; Keech, A.C.; Roselli, C.; Lubitz, S.A.; et al. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation 2020, 141, 1600–1607.
  112. Camargo, L.; França, C.; Izar, M.; Bianco, H.; Lins, L.; Barbosa, S.; Pinheiro, L.; Fonseca, F. Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy. Braz. J. Med. Biol. Res. 2014, 47, 432–437.
  113. Roth, E.M.; Taskinen, M.-R.; Ginsberg, H.N.; Kastelein, J.J.; Colhoun, H.M.; Robinson, J.G.; Merlet, L.; Pordy, R.; Baccara-Dinet, M.T. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial. Int. J. Cardiol. 2014, 176, 55–61.
  114. Becher, T.; Schulze, T.J.; Schmitt, M.; Trinkmann, F.; El-Battrawy, I.; Akin, I.; Kälsch, T.; Borggrefe, M.; Stach, K. Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells. Int. J. Cardiol. 2017, 227, 858–862.
  115. Fazio, S. The role of PCSK9 in intestinal lipoprotein metabolism: Synergism of statin and ezetimibe. Atheroscler. Suppl. 2015, 17, 23–26.
  116. Cui, C.-J.; Li, S.; Li, J.-J. PCSK9 and its modulation. Clin. Chim. Acta 2015, 440, 79–86.
  117. Olie, R.H.; Van Der Meijden, P.E.J.; Spronk, H.M.H.; Cate, H.T. Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis. Organotypic Models Drug Dev. 2020, 1–28.
  118. Korish, A.A. Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice. Arch. Med. Res. 2020, 51, 515–523.
  119. Xia, X.; Li, J.; Liang, X.; Zhang, S.; Liu, T.; Liu, J.; Arif, M.; Li, G. Ticagrelor suppresses oxidized low-density lipoprotein-induced endothelial cell apoptosis and alleviates atherosclerosis in ApoE-/- mice via downregulation of PCSK. Mol. Med. Rep. 2018, 19, 1453–1462.
  120. Luzak, B.; Boncler, M.; Rywaniak, J.; Wilk, R.; Stanczyk, L.; Czyz, M.; Rysz, J.; Watala, C. The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients. Eur. J. Pharmacol. 2011, 658, 91–97.
  121. Grdinic, A.; Vojvodic, D.; Djukanovic, N.; Colic, M.; Grdinic, A.G.; Ignjatovic, V.; Majstorovic, I.; Ilic, V.; Magic, Z.; Obradovic, S.; et al. PCI and clopidogrel: Antiplatelet responsiveness and patient characteristics. Acta Cardiol. 2011, 66, 333–340.
  122. Navarese, E.P.; Kołodziejczak, M.; Winter, M.-P.; Alimohammadi, A.; Lang, I.M.; Buffon, A.; Lip, G.Y.; Siller-Matula, J.M. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. Int. J. Cardiol. 2017, 227, 644–649.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback